Gil Roth07.19.11
George Scott, Ph.D., has been named vice president, Bioanalytical Services for PharmaNet Development Group, Inc., an inVentiv Health Company. Dr. Scott will provide leadership for PharmaNet's GLP-compliant bioanalytical laboratories in the U.S. and Canada. In addition, he will build upon PharmaNet's bioanalytical method development, validation and sample analysis services across the continuum of drug development and lead PharmaNet's geographical and service expansion strategies in bioanalysis.
"Dr. Scott has a very impressive scientific and operational experience base in bioanalysis," commented Riaz Bandali, the company's president, Early Stage Development. "He has extensive knowledge of our clients' needs and is highly regarded in the industry for his scientific expertise and his business acumen."
Prior to joining PharmaNet, Dr. Scott served as director of Pharmacokinetics and Drug Metabolism at Amgen, where he was responsible for overseeing immunochemistry and small molecule bioanalytical capabilities. He was also integrally involved in the Amgen Leadership Committee that managed strategic outsourcing decisions for small molecule and large molecule programs to global bioanalytical service providers. Prior to Amgen, Dr. Scott was responsible for establishing and growing the global ligand binding services at another CRO.
"Dr. Scott has a very impressive scientific and operational experience base in bioanalysis," commented Riaz Bandali, the company's president, Early Stage Development. "He has extensive knowledge of our clients' needs and is highly regarded in the industry for his scientific expertise and his business acumen."
Prior to joining PharmaNet, Dr. Scott served as director of Pharmacokinetics and Drug Metabolism at Amgen, where he was responsible for overseeing immunochemistry and small molecule bioanalytical capabilities. He was also integrally involved in the Amgen Leadership Committee that managed strategic outsourcing decisions for small molecule and large molecule programs to global bioanalytical service providers. Prior to Amgen, Dr. Scott was responsible for establishing and growing the global ligand binding services at another CRO.